Acquisition of Vidya Therapeutics, Inc. and Concurrent Private Placement (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands |
9 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|
Jul. 30, 2026 |
Jul. 28, 2026 |
Sep. 30, 2026 |
Dec. 31, 2025 |
|||||
| Asset Acquisition [Line Items] | ||||||||
| Preferred stock, par value | $ 0.0001 | $ 0.0001 | ||||||
| Common stock, par value | $ 0.0001 | $ 0.0001 | ||||||
| Options assumed in the Vidya Acquisition | 1,047,524 | |||||||
| Gross proceeds from issuance of private placement | $ 200,000 | |||||||
| Securities Purchase Agreement [Member] | ||||||||
| Asset Acquisition [Line Items] | ||||||||
| Gross proceeds from issuance of private placement | $ 200,000 | |||||||
| Series A Preferred Stock [Member] | ||||||||
| Asset Acquisition [Line Items] | ||||||||
| Stock issued during period shares new issues | 306,574.202 | 0 | ||||||
| Share issued price per shares | [1] | $ 1.22119 | ||||||
| Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | ||||||||
| Asset Acquisition [Line Items] | ||||||||
| Stock issued during period shares new issues | 163,774.679 | |||||||
| Common shares issuable upon conversion of preferred stock | 163,774,679 | |||||||
| Share issued price per shares | $ 1,221.19 | |||||||
| Conversion price per share | $ 1.22119 | |||||||
| Vidya Therapeutics, Inc. [Member] | ||||||||
| Asset Acquisition [Line Items] | ||||||||
| Total consideration | [2] | $ 175,000 | ||||||
| Transaction costs | $ 2,700 | |||||||
| Vidya Therapeutics, Inc. [Member] | Series A Non-Voting Convertible Preferred Stock [Member] | ||||||||
| Asset Acquisition [Line Items] | ||||||||
| Shares issued on consideration | 142,254.972 | |||||||
| Vidya Therapeutics, Inc. [Member] | Series A Preferred Stock [Member] | ||||||||
| Asset Acquisition [Line Items] | ||||||||
| Shares issued on consideration | 142,254,972 | |||||||
| Preferred stock, par value | $ 0.0001 | |||||||
| Conversion of shares | 1,000 | |||||||
| Common stock, par value | $ 0.0001 | |||||||
| Total consideration | $ 175,000 | |||||||
| Description for equity interest | As a result of the acquisition and related private placement transaction, our equity holders immediately prior to the Vidya Acquisition owned approximately 1.4% of our common stock, equity holders of Vidya immediately prior to the Vidya Acquisition owned approximately 46.0% of our common stock and investors in the 2026 Private Placement owned approximately 52.6% of our common stock, in each case, calculated on a fully diluted basis (assuming the conversion in full of the Series A Preferred Stock) and based on our and Vidya’s implied equity values. | |||||||
| Vidya Therapeutics, Inc. [Member] | Series A Preferred Stock [Member] | Merger Agreement [Member] | ||||||||
| Asset Acquisition [Line Items] | ||||||||
| Options assumed in the Vidya Acquisition | 1,047,524 | |||||||
| Total consideration | $ 175,400 | |||||||
| Transaction costs | 2,700 | |||||||
| Vidya Therapeutics, Inc. [Member] | Series A Preferred Stock [Member] | Merger Agreement [Member] | Advisor [Member] | ||||||||
| Asset Acquisition [Line Items] | ||||||||
| Acquisition costs | $ 700 | |||||||
| Stock issued during period shares new issues | 544.551 | |||||||
| ||||||||